摘要
目的评价依达拉奉联合奥扎格雷钠治疗老年糖尿病患者急性脑梗死的疗效和安全性。方法 64例老年急性脑梗死患者,以往确诊2型糖尿病,随机分为依达拉奉联合奥扎格雷钠治疗组和对照组,分别在治疗前,治疗后1、2、3周,采用日常生活能力(ADL)量表、欧洲卒中评分(ESS)等神经心理分析工具对患者的疗效进行评价,并观察有无出血或转氨酶升高等不良反应,进行安全性评估。结果依达拉奉联合奥扎格雷钠治疗组的ESS及ADL评分较对照组均有明显改善(P<0.05分别)。在研究期间,1例患者出现轻度转氨酶升高,不良事件发生率为3.1%。依达拉奉的安全性和依从性良好。结论依达拉奉联合奥扎格雷钠治疗老年糖尿病患者急性脑梗死安全有效。
Objective To evaluate the therapeutic effects and safety of edaravone combined with sodium ozagrel on senile diabetic mellitus patients with acute cerebral infarct. Methods An open trail was carried out with 64 senile diabetes mellitus patients with acute cerebral infarct. Patients were treated with edaravone combined with sodium ozagrel for 2 weeks. The neu- ro-psyeologieal scale of ESS and ADL were used to evaluate patient＇s therapeutic effect before therapy and lst,2nd, 3th week after treatment. The adverse effects, such as increase of aminotransferase or hemorrhage were monitored at the same time to e valuate the safety of these two drugs. Results After treatment, the ESS and ADL score of patients of edaravone combined with sodium ozagrel group were improved significantly （P〈0.05）. Conclusion Edaravone combined with sodium ozagrel are effective and safe on senile diabetes mellitus patients with acute cerebral infarct.
出处
《中国实用神经疾病杂志》
2010年第15期29-30,共2页
Chinese Journal of Practical Nervous Diseases
关键词
老年
糖尿病
脑梗死
依达拉奉
奥扎格雷钠
Senile
Diabetes mellitus
Cerebral infarct
Edaravone
Sodium ozalzrel
